Document Type: Original Article

Authors

1 Immunology Research Center, BuAli Research Institute, Mashhad University of Medical Sciences, Iran

2 Center for Integrated Genomic Medical Research, The University of Manchester, Manchester, UK

3 Immunology Research Group, Faculty of Life sciences, The University of Manchester, UK

4 Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

5 Transplantation Laboratory, Central Manchester, Healthcare Trust, Manchester, UK

6 ARC Epidemiology Unit, The University of Manchester, Manchester, UK

Abstract

Background: Human T cell lymphotropic virus type I (HTLV-I)-associated myelopa-thy/tropical spastic paraparesis (HAM/TSP) is an inflammatory disease which occurs in less than 2% of HTLV-I -infected individuals. High proviral load, high HTLV-I-specific CD8+ cytotoxic T lymphocyte frequency (CTL) and host genetic factors such as HLA all appear to be associated with HTLV-I infection. Previous studies have shown that HLA-DRB1*01 increases the risk of HAM/TSP in Japanese HTLV-I infected individu-als.
Objective: To investigate the association between HLA class II DRB1 alleles and HLA class I alleles (HLA-Cw*08, B54, A*02 and A-30) in HTLV-I infected individu-als in Mashhad.
Methods: Here we determined the frequency of HLA class II DRB1, using INNO-LIPA reverse hybridization line probe assay, and HLA class I alleles (HLA-Cw*08,B54, A*02 and A-30) by PCR-SSCP method in healthy controls, HAM/TSP patients and HTLV-I infected individuals born and resident in Mashhad.
Results: The frequency of HLA-DRB1*01 alleles in this population was different from other areas of Iran. The frequency of HLA-DRB1*01 was significantly increased in HAM/TSP patients compared with carriers (p 0.028; OR=9.4). The frequency of HLA-Cw*08 was also significantly increased in HAM/TSP patients compared with controls (p=0.03; OR=13.5).
Conclusion: Our results may suggest that possession of HLA-DRB1*01 increases the risk of HAM/TSP in HTLV-I-infected individuals and HLA-Cw*08 correlates with low CTL immune response in HAM/TSP patients.

Keywords